Preventive Treatment Of Episodic Migraine In Adults — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for preventive treatment of episodic migraine in adults. 20 active patents protecting 1 drugs from 1+ originators. First major cliff: 2031. Daily refresh.

1
Approved drugs
20
Active US patents
56/100
Avg vulnerability
$201M
Annual revenue covered

Originators in Preventive Treatment Of Episodic Migraine In Adults

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

AbbVie 20 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating preventive treatment of episodic migraine in adults. Each bar = one year. Y-axis scaled to peak year (3 patents).

3
31
3
32
3
33
3
35
3
39

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Qulipta
ATOGEPANT
 AbbVie 20 56 $201M 2031-11-10

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12383545 Qulipta method of use 75 2039-06-06
12383545 Qulipta method of use 75 2039-06-06
12383545 Qulipta method of use 75 2039-06-06
12090148 Qulipta method of use 75 2041-07-29
12090148 Qulipta method of use 75 2041-07-29
12090148 Qulipta method of use 75 2041-07-29
12465598 Qulipta method of use 75 2042-09-27
12350259 Qulipta method of use 75 2043-02-27
9499545 Qulipta method of use 68 2031-11-10
9499545 Qulipta method of use 68 2031-11-10

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9850246 Qulipta composition of matter 4 2033-03-13
9850246 Qulipta composition of matter 4 2033-03-13
9850246 Qulipta composition of matter 4 2033-03-13
10117836 Qulipta formulation 42 2035-01-30
10117836 Qulipta formulation 42 2035-01-30
10117836 Qulipta formulation 42 2035-01-30
8754096 Qulipta method of use 62 2032-07-19
8754096 Qulipta method of use 62 2032-07-19
8754096 Qulipta method of use 62 2032-07-19
9499545 Qulipta method of use 68 2031-11-10

Related